cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.12732044
title: Vibronic excitations in CeAuAl3 (p10684)

description: <b>Abstract:</b>Hybridized excitations that comprise of well-known and well-understood collective modes have received increasing interest as the possible origin of novel functionalities and unconventional materials properties. Recently, TOF spectroscopy on CeCuAl3 has provided putative evidence for a so-called vibronic mode – a combined crystal field - phonon excitation. We have found such excitation in single crystalline samples of CeAuAl3 during a short test experiment on PANDA (despite recent TOF study on polycrystals claiming the opposite).<br>We propose to determine the details of that excitation as well as its temperature dependence down to 3 K. <br><b>Place:</b>Heinz Meier-Leibnitz Zentrum, Garching, Germany (MLZ)<br><b>Instruments:</b><br>PUMA (https://mlz-garching.de/puma)<b>Date: </b><br>Wed, 06. May 2015 to Fri, 15. May 2015<b>Disclaimer:</b>Abstract is not modified version of the abstract from original scientific proposal submitted to MLZ. Data are published exactly as they were send to us after the end of experiments (automatic email by NICOS). Authenticity of the data can be verified by the data scientists at MLZ, feel free to contact them.<br>
DOI: 10.6084/m9.figshare.12732125
title: maps and matrices

description: activation maps and matrices
DOI: 10.6084/m9.figshare.12732125.v1
title: maps and matrices

description: activation maps and matrices
DOI: 10.6084/m9.figshare.12732044.v1
title: Vibronic excitations in CeAuAl3 (p10684)

description: <b>Abstract:</b>Hybridized excitations that comprise of well-known and well-understood collective modes have received increasing interest as the possible origin of novel functionalities and unconventional materials properties. Recently, TOF spectroscopy on CeCuAl3 has provided putative evidence for a so-called vibronic mode – a combined crystal field - phonon excitation. We have found such excitation in single crystalline samples of CeAuAl3 during a short test experiment on PANDA (despite recent TOF study on polycrystals claiming the opposite).<br>We propose to determine the details of that excitation as well as its temperature dependence down to 3 K. <br><b>Place:</b>Heinz Meier-Leibnitz Zentrum, Garching, Germany (MLZ)<br><b>Instruments:</b><br>PUMA (https://mlz-garching.de/puma)<b>Date: </b><br>Wed, 06. May 2015 to Fri, 15. May 2015<b>Disclaimer:</b>Abstract is not modified version of the abstract from original scientific proposal submitted to MLZ. Data are published exactly as they were send to us after the end of experiments (automatic email by NICOS). Authenticity of the data can be verified by the data scientists at MLZ, feel free to contact them.<br>
DOI: 10.6084/m9.figshare.12731981
title: Supplementary Material for: Effects of LCZ696 on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials

description: <b><i>Background:</i></b> LCZ696 (sacubitril/valsartan), a ﬁrst-in-class angiotensin receptor-neprilysin inhibitor, can significantly reduce blood pressure in patients with heart failure. We performed this meta-analysis to determine the antihypertensive effect of LCZ696 in patients with hypertension. <b><i>Methods:</i></b> Randomized controlled trials were searched in MEDLINE, the Cochrane Library, and Clinicaltrials.gov. Twelve studies with a total of 6,064 participants were included. <b><i>Results:</i></b> Compared with angiotensin receptor blockers (ARBs), LCZ696 100 mg caused a significant reduction in systolic blood pressure (SBP) (mean difference [MD] –1.58 mm Hg, 95% confidence interval [CI] –2.09 to –1.07, <i>p</i> &lt; 0.05) and diastolic blood pressure (DBP) (MD –0.66 mm Hg, 95% CI –0.98 to –0.33, <i>p</i> &lt; 0.05). LCZ696 200 mg caused a significant reduction in SBP (MD –4.94 mm Hg, 95% CI –6.54 to –3.35, <i>p</i> &lt; 0.05), DBP (MD –2.24 mm Hg, 95% CI –2.74 to –1.75, <i>p</i> &lt; 0.05), 24-h ambulatory SBP (24 h ASBP; MD –3.69 mm Hg, 95% CI –4.80 to –2.58, <i>p</i> &lt; 0.05), and 24-h ADBP (MD –1.71 mm Hg, 95% CI –2.13 to –1.28, <i>p</i> &lt; 0.05). LCZ696 400 mg caused a significant reduction in SBP (MD –6.25 mm Hg, 95% CI –7.90 to –4.61, <i>p</i> &lt; 0.05), DBP (MD -2.30 mm Hg, 95% CI –2.80 to –1.80, <i>p</i> &lt; 0.05), 24-h ASBP (MD –4.31 mm Hg, 95% CI –6.56 to –2.07, <i>p</i> &lt; 0.05), and 24 h ADBP (MD –1.69 mm Hg, 95% CI –2.59 to –0.79, <i>p</i> &lt; 0.05). Compared with LCZ696 200 mg, LCZ696 400 mg caused a significant reduction in SBP (MD 1.71 mm Hg, 95% CI 1.15 to 2.27, <i>p</i> &lt; 0.05), DBP (MD 0.90 mm Hg, 95% CI 0.65 to 1.16, <i>p</i> &lt; 0.05), 24-h ASBP (MD 1.50 mm Hg, 95% CI 0.84 to 2.17, <i>p</i> &lt; 0.05), and 24-h ADBP (MD 0.76 mm Hg, 95% CI 0.47 to 1.06, <i>p</i> &lt; 0.05). <b><i>Conclusions:</i></b> The blood pressure-lowering effect of LCZ696 is dose-related. This meta-analysis confirms the antihypertensive effects of LCZ696.
DOI: 10.6084/m9.figshare.12731972
title: Sanger sequences of R. aquaticus isolate

description: Sanger sequence data of R. aquaticus isolate.
DOI: 10.6084/m9.figshare.12731978
title: Assembly and reads of R. aquaticus isolate

description: Raw reads of MISeq sequencing of R. aquaticus LMG 30558 and IDBA-UD assembly.
DOI: 10.6084/m9.figshare.12731978.v1
title: Assembly and reads of R. aquaticus isolate

description: Raw reads of MISeq sequencing of R. aquaticus LMG 30558 and IDBA-UD assembly.
DOI: 10.6084/m9.figshare.12731960
title: Supplementary Material for: Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis

description: <b><i>Introduction/Objective:</i></b> Lenvatinib demonstrated efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the randomized phase III REFLECT trial. Considering the discrepancies in patients between clinical trial data and daily practice, an account of practical experience is needed. <b><i>Methods:</i></b> We conducted a multicenter retrospective analysis in which 3 tertiary referral centers participated. A total of 92 patients with advanced HCC treated with lenvatinib between September 2018 and January 2020 were analyzed. <b><i>Results:</i></b> Lenvatinib was used as the first-line therapy for 67 (72.8%) patients, and for 25 (27.2%) patients previously treated with other systemic therapy including immune checkpoint inhibitors. At the time of initiation of lenvatinib, 74 (80.4%) and 18 (19.6%) patients were classified as Child-Pugh A and B, respectively. Thirty-five patients (38.0%) had extensive disease that would have excluded them from the REFLECT trial. In the Child-Pugh A group, the response rate graded according to the Response Evaluation Criteria in Solid Tumors v1.1 was 21.1%, median progression-free survival (PFS) was 4.6 (95% confidence interval [CI] 3.1–6.1) months, and overall survival (OS) was 10.7 (95% CI 4.8–16.5) months for patients treated with first-line lenvatinib (<i>n</i> = 57). With second- or later-line lenvatinib (<i>n</i> = 17), median PFS and OS were 4.1 (95% CI 3.1–5.1) and 6.4 (95% CI 5.1–7.7) months, respectively. In the Child-Pugh B group (<i>n</i> = 18), median PFS and OS were 2.6 (95% CI 0.6–4.6) and 5.3 (95% CI 2.0–8.5) months, respectively. The most common grade 3–4 toxicities were hyperbilirubinemia (<i>n</i> = 8; 8.7%), AST elevation (<i>n</i> = 6; 6.5%), and diarrhea (<i>n</i> = 5; 5.4%) across all study patients. <b><i>Conclusions:</i></b> In this real-world study, lenvatinib was found to be well tolerated and effective in more heterogeneous HCC patient populations.
DOI: 10.6084/m9.figshare.12731972.v1
title: Sanger sequences of R. aquaticus isolate

description: Sanger sequence data of R. aquaticus isolate.
DOI: 10.6084/m9.figshare.12731960.v1
title: Supplementary Material for: Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis

description: <b><i>Introduction/Objective:</i></b> Lenvatinib demonstrated efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the randomized phase III REFLECT trial. Considering the discrepancies in patients between clinical trial data and daily practice, an account of practical experience is needed. <b><i>Methods:</i></b> We conducted a multicenter retrospective analysis in which 3 tertiary referral centers participated. A total of 92 patients with advanced HCC treated with lenvatinib between September 2018 and January 2020 were analyzed. <b><i>Results:</i></b> Lenvatinib was used as the first-line therapy for 67 (72.8%) patients, and for 25 (27.2%) patients previously treated with other systemic therapy including immune checkpoint inhibitors. At the time of initiation of lenvatinib, 74 (80.4%) and 18 (19.6%) patients were classified as Child-Pugh A and B, respectively. Thirty-five patients (38.0%) had extensive disease that would have excluded them from the REFLECT trial. In the Child-Pugh A group, the response rate graded according to the Response Evaluation Criteria in Solid Tumors v1.1 was 21.1%, median progression-free survival (PFS) was 4.6 (95% confidence interval [CI] 3.1–6.1) months, and overall survival (OS) was 10.7 (95% CI 4.8–16.5) months for patients treated with first-line lenvatinib (<i>n</i> = 57). With second- or later-line lenvatinib (<i>n</i> = 17), median PFS and OS were 4.1 (95% CI 3.1–5.1) and 6.4 (95% CI 5.1–7.7) months, respectively. In the Child-Pugh B group (<i>n</i> = 18), median PFS and OS were 2.6 (95% CI 0.6–4.6) and 5.3 (95% CI 2.0–8.5) months, respectively. The most common grade 3–4 toxicities were hyperbilirubinemia (<i>n</i> = 8; 8.7%), AST elevation (<i>n</i> = 6; 6.5%), and diarrhea (<i>n</i> = 5; 5.4%) across all study patients. <b><i>Conclusions:</i></b> In this real-world study, lenvatinib was found to be well tolerated and effective in more heterogeneous HCC patient populations.
DOI: 10.6084/m9.figshare.12731909
title: sm_data2.xlsx

description: This table contains the results of experimental size manipulation in Hydra oligactis. The following variables are included:<br>#Plate_number: size manipulation set containing four individuals#Sex: either C2/7 (male strain) or X11/14 (female strain)#Exp_group: one of "enlarged", "reduced", "ctrl1" or "ctrl2". Enlarged and reduced form a pair of size manipulated individuals while ctrl1 and ctrl2 form a pair of control individuals.#pre_area: area of body column prior to experimental treatment in square mm#post_area: area of body column after experimental treatment in square mm#Gonads: Maximum no. testes in males or total no. eggs in females#Cooling_date: when the set was moved from 18 to 8 degrees Celsius. This is exactly one day post-manipulation#Start_date: The date when the first gonads were detected#Fate: one of: "fail"-grafting unsuccesful, died shortly after cooling, was sex-changed or host/graft remained asexual; "dead"-disappeared during the experiment or was fully necrotic by the end of the experiment; "regenerated"-regenerated and reverted to asexual reproduction following sex<br>
DOI: 10.6084/m9.figshare.12731909.v1
title: sm_data2.xlsx

description: This table contains the results of experimental size manipulation in Hydra oligactis. The following variables are included:<br>#Plate_number: size manipulation set containing four individuals#Sex: either C2/7 (male strain) or X11/14 (female strain)#Exp_group: one of "enlarged", "reduced", "ctrl1" or "ctrl2". Enlarged and reduced form a pair of size manipulated individuals while ctrl1 and ctrl2 form a pair of control individuals.#pre_area: area of body column prior to experimental treatment in square mm#post_area: area of body column after experimental treatment in square mm#Gonads: Maximum no. testes in males or total no. eggs in females#Cooling_date: when the set was moved from 18 to 8 degrees Celsius. This is exactly one day post-manipulation#Start_date: The date when the first gonads were detected#Fate: one of: "fail"-grafting unsuccesful, died shortly after cooling, was sex-changed or host/graft remained asexual; "dead"-disappeared during the experiment or was fully necrotic by the end of the experiment; "regenerated"-regenerated and reverted to asexual reproduction following sex<br>
DOI: 10.6084/m9.figshare.12731704
title: Additional file 1 of The molecular effect of a polymorphic microRNA binding site of Wolfram syndrome 1 gene in dogs

description: Additional file 1.
DOI: 10.6084/m9.figshare.12731704.v1
title: Additional file 1 of The molecular effect of a polymorphic microRNA binding site of Wolfram syndrome 1 gene in dogs

description: Additional file 1.
DOI: 10.6084/m9.figshare.12731671
title: Additional file 9 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 9: Table S7. Location and alignments of N protein peptides resulting from rare deletions within N gene.
DOI: 10.6084/m9.figshare.12731668
title: Additional file 8 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 8: Table S6. Peptide identification report from MS/MS based search of Chymotrypsin digested proteins.
DOI: 10.6084/m9.figshare.12731665
title: Additional file 7 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 7: Table S5. A list of unique peptides detected by MS/MS and their parent protein.
DOI: 10.6084/m9.figshare.12731668.v1
title: Additional file 8 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 8: Table S6. Peptide identification report from MS/MS based search of Chymotrypsin digested proteins.
DOI: 10.6084/m9.figshare.12731665.v1
title: Additional file 7 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 7: Table S5. A list of unique peptides detected by MS/MS and their parent protein.
DOI: 10.6084/m9.figshare.12731671.v1
title: Additional file 9 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 9: Table S7. Location and alignments of N protein peptides resulting from rare deletions within N gene.
DOI: 10.6084/m9.figshare.12731656
title: Additional file 4 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 4: Table S3. Transcript structure and ORF assignment table. Similar to supplementary 2, a table outlining the distinct structures of transcripts, how many times a particular type of transcript was detected and which ORFS the transcripts could code for. In this case all transcripts are listed irrespective of where the transcription start is mapped to.
DOI: 10.6084/m9.figshare.12731659
title: Additional file 5 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 5: Table S4. Start locations and internal transcript boundaries. A list of the number of ties a genome location is used as a transcript start, transcript stop or is noted at the location of a transcript boundary (akin to an exon-intron boundary).
DOI: 10.6084/m9.figshare.12731653
title: Additional file 3 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 3: Table S2. Transcript structure and ORF assignment table. A table outlining the distinct structures of transcripts, how many times a particular type of transcript was detected and which ORFS the transcripts could code for. Only transcripts that start within the leader TRS are considered.
DOI: 10.6084/m9.figshare.12731656.v1
title: Additional file 4 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 4: Table S3. Transcript structure and ORF assignment table. Similar to supplementary 2, a table outlining the distinct structures of transcripts, how many times a particular type of transcript was detected and which ORFS the transcripts could code for. In this case all transcripts are listed irrespective of where the transcription start is mapped to.
DOI: 10.6084/m9.figshare.12731659.v1
title: Additional file 5 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 5: Table S4. Start locations and internal transcript boundaries. A list of the number of ties a genome location is used as a transcript start, transcript stop or is noted at the location of a transcript boundary (akin to an exon-intron boundary).
DOI: 10.6084/m9.figshare.12731647
title: Additional file 1 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 1. A text file delimitating the locations of known features on the SARS-CoV-2 genome.
DOI: 10.6084/m9.figshare.12731650
title: Additional file 2 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 2: Table S1. Transcripts coding for an ORF count table. A table of the number of times transcripts were detected that would code for any given ORF. This considers only transcripts that start within the leader region of the viral genome.
DOI: 10.6084/m9.figshare.12731653.v1
title: Additional file 3 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 3: Table S2. Transcript structure and ORF assignment table. A table outlining the distinct structures of transcripts, how many times a particular type of transcript was detected and which ORFS the transcripts could code for. Only transcripts that start within the leader TRS are considered.
DOI: 10.6084/m9.figshare.12731650.v1
title: Additional file 2 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 2: Table S1. Transcripts coding for an ORF count table. A table of the number of times transcripts were detected that would code for any given ORF. This considers only transcripts that start within the leader region of the viral genome.
DOI: 10.6084/m9.figshare.12731640
title: Additional file 2 of Multi-trait multi-locus SEM model discriminates SNPs of different effects

description: Additional File 2. Description of phenotypic trait.
DOI: 10.6084/m9.figshare.12731647.v1
title: Additional file 1 of Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

description: Additional file 1. A text file delimitating the locations of known features on the SARS-CoV-2 genome.
DOI: 10.6084/m9.figshare.12731640.v1
title: Additional file 2 of Multi-trait multi-locus SEM model discriminates SNPs of different effects

description: Additional File 2. Description of phenotypic trait.
DOI: 10.6084/m9.figshare.12731622
title: Additional file 1 of The Lebanese left ventricular assist device experience, a success story despite the odds

description: Additional file 1.
DOI: 10.6084/m9.figshare.12731622.v1
title: Additional file 1 of The Lebanese left ventricular assist device experience, a success story despite the odds

description: Additional file 1.
DOI: 10.6084/m9.figshare.12731556
title: Additional file 3 of 3D printed spermathecae as experimental models to understand sperm dynamics in leaf beetles

description: Additional file 3 Supplementary information 3, Movies.MP4. Fluid dynamics tests performed by the 3D printer. Supplementary information 3, Movie 1. Protuberance model, first 30 pumping cycles shown. The result was recorded at 50 fps. Supplementary information 3, Movie 2. No protuberance model, first 30 pumping cycles. The result was recorded at 50 fps.
DOI: 10.6084/m9.figshare.12731553
title: Additional file 2 of 3D printed spermathecae as experimental models to understand sperm dynamics in leaf beetles

description: Additional file 2 Supplementary information 2, a script 1.txt. The script used for the fluid dynamics test described in the main text and including commands to the 3D printer to move a stick to contract and relax the C-arms of the models with an absolute velocity.
DOI: 10.6084/m9.figshare.12731559
title: Additional file 4 of 3D printed spermathecae as experimental models to understand sperm dynamics in leaf beetles

description: Additional file 4 Supplementary information 4, figures.jpeg. The fluid dynamics tests (first pumping movement, outflow) were performed by the experimenter’s fingers. Supplementary information 4, Fig. 1. Transparent flexible models and fluid dynamics tests (first pumping movement, outflow) using the Agelastica alni spermatheca models with a realistic internal protuberance (left column, highlighted with red dashed lines) and without the protuberance (right column). (a-a’) The models fully immersed in 1,2-propanediol. (b-b’) Sudan Red in 1,2-propanediol was injected. (c-e’) The first pumping cycle filmed at 50 fps, and still images at different conditions are exhibited. The solid white arrows show the direction of the distal C-arm movement. The black arrows indicate a marked shift of the injected ink spots in the models. The times listed in each image are the time after pumping started. (f-f’) Schemes of the observed outflow in the first pumping cycle. Supplementary information 4, Fig. 1 (cont.). Transparent flexible models and fluid dynamics tests (first pumping, inflow) using the Agelastica alni spermatheca models with a realistic internal protuberance (left column, highlighted with red dashed lines) and without the protuberance (right column). (g-h’) The first pumping cycle filmed at 50 fps, with still images shown under different conditions. The solid white arrows show directions of the distal C-arm movement. The black arrows show a marked shift of the fluid in the models. (i-i’) The inflow at the second pumping cycle. (j-j’) Schemes of the observed inflow during the first two pumping cycles. The light-pink circles in the schemes indicate the original locations of the injected ink. Supplementary information 4, Fig. 2. Fluid dynamics in subsequent pumping cycles. (a-a’) Sudan Red in 1,2-propanediol was injected. (b-b’) After the C-arms were pumped ten times. (c-c’) After the C-arms were pumped 20 times, but in the protuberance model at the 11th pumping cycle, Sudan Red partly leaked (Supplementary Information 5, Movie 2) from a lateral crack. However, similar results were observed before the lateral crack occurred. (d-d’) After the C-arms were pumped 30 times. The visible unmixed ink drops are marked with solid black lines.